

# EYECHEQ

---

## The world's first and only AI-driven, tech-enabled vision and health platform

Point-of-care retinal screening deployed across labs, clinics, and retail.

FDA-cleared device

HIPAA · SOC 2

Commercial revenue live

Investor Presentation · 2026

[www.eyecheq.com](http://www.eyecheq.com)



## THE PROBLEM

# Everyone needs an eye exam

90%+ of blindness is preventable when detected early, yet access, cost, and awareness keep patients out of care.



## High

**COST OF CARE**

Specialty eye care is expensive and often out of reach for the patients who need screening most.



## 26%

**NEVER SEE AN EYE DOCTOR**

Only ~50% of adults visit annually as recommended — leaving a vast unscreened population.



## Unaware

**PATIENTS AT RISK**

Most early eye and systemic disease is asymptomatic; patients don't know to seek care until damage is done.

## THE SOLUTION

# A national screening footprint

Located in labs, doctors' offices, and retail healthcare settings — meeting patients where they already are.



### Patent-pending point-of-care platform

Purpose-built fixed stations for high-throughput community screening.



### Simple 5-minute patient experience

Guided, tech-enabled workflow — no on-site clinician required.



### FDA-cleared / registered devices

Medical-grade retinal camera, autorefractor, and visual acuity.



### Screening patients today

Live in market generating commercial revenue.








*EyeCheq station deployed at Quest Diagnostics*




TEAM

# World-class leadership

Proven healthcare leaders and entrepreneurs with successful exits.

 <p><b>Rashid Taher, MD</b> CEO</p> <p>Cofounder, Pediatric Radiology of America (acq. Aris Teleradiology)</p>	 <p><b>Ali Khoshnevis, OD</b> CEO, CLRA · CSO, EyeCheq</p> <p>Cofounder, PxSource (acq. RevolutionEHR); Tesser Health (acq. ELMC)</p>	 <p><b>Chris Grant</b> CCO</p> <p>EVP, Quest Diagnostics; EVP, Kaiser Permanente</p>	 <p><b>Allen Hersh</b> Chief Development Officer</p> <p>Cofounder, Harmony Dental (acq. MB2); CMO, VieMed (IPO)</p>	 <p><b>Jordan Duggan</b> Chief Technology Officer</p> <p>VP Product &amp; Dev, InspectionXpert; VP Product &amp; Dev, Virtru</p>
---	--	---	--	---

## ADVISORY BOARD

 <p><b>Khan Siddiqui, MD</b> Co-Founder</p> <p>Founder, HIGI (acq. Babylon); CMO, Hyperfine (IPO)</p>	 <p><b>Jyoti Gupta, PhD</b> Advisor</p> <p>CEO/President, GE Healthcare Women; CEO, Volk Optical</p>	 <p><b>Ruwan Silva, MD</b> Chief Medical Officer</p> <p>Stanford University School of Medicine; ABO Diplomate</p>	 <p><b>Jai Parekh, MD</b> CIO</p> <p>Former CMO, Allergan; surgeon, entrepreneur</p>
--	---	--	---

TEAM

# Engineering & data science

Experts in biomedical engineering, machine learning, and computer science.



**Sloan Zimmerman**  
Biomedical Engineer

Harvard (BS), OSU (MS); NASA,  
Cleveland Clinic



**Josh Barclay**  
Machine Learning Engineer

MS, Georgia Tech; Engineer, NCSU



**Samantha Yeager**  
Software Engineer

Front-end & UI/UX design



**Ryan Mee**  
Software Engineer

Computer Science, NCSU; front-  
end & design



**Rob Synder**  
Software Engineer

Computer Science, DePauw;  
Kaplan, Aprimo, Bluelock

TRACTION

# Early customers, national scale

**8,000+**

Total addressable locations

**250M+**

Patients reachable in the U.S.

**\$1B+**

Platform opportunity — screening, media & data, U.S. + international

EARLY CUSTOMER COMMITMENTS

**Walmart**

In Pilot

**Quest Diagnostics**

Under Contract

**VSP**

Under Contract

**Atrium Health**

Under Contract

# The retail opportunity

Walmart · Sam's Club · Target · Costco — a ~20,000-location opportunity.



**20K**

RETAIL LOCATIONS

A vast existing footprint of vision centers ready for tech-enabled screening.



**3K+**

SITES LACK PROVIDERS

Tech-enabled operation extends optical services where clinicians aren't available.



**\$250**

AVG. REVENUE / PATIENT

New high-margin revenue per screening, plus downstream eyewear sales.

# The clinic, lab & pharmacy opportunity

CVS · Walgreens · Quest Diagnostics · Atrium Health — a ~100,000-location opportunity.



## 100K

LOCATIONS

Pharmacies, labs, and clinics already serving high volumes of at-risk patients.



## Gap

DIABETIC EYE EXAM

Diabetic retinal exams largely aren't being performed — a major HEDIS care gap.



## \$250

AVG. REVENUE / PATIENT

Close care gaps for health plans while adding a new recurring revenue line.

# Two flexible deployment models

	Customer Buys Kiosk "CBK"	Platform as a Service (PaaS)
<b>Summary</b>	Client buys the kiosk and contracts EyeCheq to deliver tele-optometry to its customers.	Client leases the kiosk from EyeCheq and contracts directly with health plans.
<b>Example deployment</b>	Walmart	Quest Diagnostics
<b>Client value proposition</b>	Sell glasses	Close care gaps (Medicare Advantage)
<b>Scope of EyeCheq services</b>	Retinal screening + corrective-lens Rx	Retinal screening + basic visual acuity
<b>Kiosk purchase price</b>	\$50,000	N/A (leased)
<b>EyeCheq business model</b>	Sell kiosks + exam fee per patient	Lease fee (client owns monetization)
<b>Monthly revenue / unit</b>	<b>\$13,000</b>	<b>\$3,500 – \$5,000</b>
<b>Forecast gross margin (2026)</b>	<b>52%</b>	<b>76%</b>

# Three compounding revenue layers

Every screening generates revenue today — and builds media reach and a proprietary data asset that monetize as the network scales — each layer extends internationally beyond the U.S. footprint.



## Live

### 1 · SCREENING REVENUE

Per-patient exam fees and kiosk leases across CBK and PaaS models. 100% of the base-case pro forma — generating revenue now.



## 2028+

### 2 · MEDIA & ENGAGEMENT

Sponsored on-kiosk and portal content for pharma, vision plans, and eyewear. Scales only after critical-mass deployment; excluded from base case.




## Asset

### 3 · DATA & AI LICENSING

Millions of consented retinal images paired with same-visit Quest lab data — the substrate for systemic-disease AI and strategic value at exit.

# Every screening makes the platform more valuable



## OUTCOMES

# Strong clinical results & utilization

EyeCheq's success in the market has created organic demand.



# 30%

Increase in demand for screenings



# 47%

Early detection of eye disease



# 95%

Patient satisfaction




# Later-stage deals across the U.S.

Health Plans	Retailers	Labs	Health Systems
<ul style="list-style-type: none"><li>• Florida Blue</li><li>• Aetna</li><li>• Cigna</li><li>• HealthFirst Health Plans</li><li>• Centene Corporation</li><li>• Health Plan of San Joaquin</li><li>• Mountain Valley Health Plan</li></ul>	<ul style="list-style-type: none"><li>• Sam's Club</li><li>• Target</li><li>• Costco</li><li>• EssilorLuxottica</li><li>• Albertsons</li></ul>	<ul style="list-style-type: none"><li>• LabCorp</li><li>• Sonora Quest Laboratories</li></ul>	<ul style="list-style-type: none"><li>• Kaiser Permanente</li><li>• Bascom Palmer Eye Institute (UM Health)</li></ul>

# From commercial launch to reimbursable RPM



# The only tech-enabled medical platform




# Pro forma

41 stations deployed in 2026, scaling to nearly 1,000 stations and \$42M revenue by 2029.

\$M / Stations	2026	2027	2028	2029
Stations deployed (year)	41	222	324	382
Cumulative stations	41	263	587	969
Revenue	\$2.0	\$13.9	\$26.6	\$41.8
Gross margin	71%	66%	73%	77%
EBITDA	\$0.7	\$5.6	\$15.0	\$26.8
EBITDA margin	34%	40%	56%	64%


REVENUE vs. EBITDA (\$M)



Cash-basis pro forma across lease and retail deployment models; year-1 hardware financed via Med One equipment leasing.

THE ASK

# Raising \$10M to scale a proven platform



USE OF FUNDS



---

# Appendix

Exit scenarios · Device & FDA status · Patient results · Security & compliance · Data strategy · Comparables



# Exit valuation scenarios

**Illustrative enterprise value** applying market EBITDA multiples to projected 2029 EBITDA of \$26.8M.



*Based on 2029 EBITDA of \$26.8M from the cash-basis pro forma; excludes media and data-licensing upside. Platform/data comparables trade on revenue multiples, supporting outcomes above this range. Illustrative only — not a forecast.*

# What data, media & licensing businesses are worth

Health Data	Point-of-Care Media	Eye AI & Devices	The Takeaway
<ul style="list-style-type: none"> <li>• Flatiron Health — acq. Roche, \$1.9B</li> <li>• Tempus AI — NASDAQ IPO 2024</li> <li>• Komodo Health — \$3.3B valuation</li> <li>• Truveta — health-system data consortium</li> <li>• 23andMe × GSK — \$300M data license</li> <li>• Verana Health — ophthalmic real-world data</li> <li>• IQVIA — RWD licensing at scale</li> </ul>	<ul style="list-style-type: none"> <li>• Doximity — pharma media, NYSE</li> <li>• PatientPoint — POC advertising network</li> <li>• CheckedUp — specialty POC media</li> <li>• GoodRx — manufacturer ad solutions</li> <li>• Health Media Network</li> </ul>	<ul style="list-style-type: none"> <li>• Digital Diagnostics — autonomous AI</li> <li>• Notal Vision — home retinal RPM</li> </ul>	<ul style="list-style-type: none"> <li>• Data &amp; media assets are valued on revenue multiples, not device EBITDA</li> <li>• Each layer EyeCheq adds re-rates the exit math upward</li> </ul>

# EyeCheq station & FDA status



## Medical Stand

FDA Class I Registered



## Autorefractor

FDA Class I Registered



## Visual Acuity

FDA Class I Registered



## Retinal Camera

FDA Class II – 510(k) Cleared

# Patient results, delivered through the portal

## Distance Vision

TAKE ACTION

Plain-language vision score with a Snellen reference. Below-normal results trigger a corrective-lens recommendation and a prompt to see an eye doctor.

## Retinal Picture

URGENT NEED

Color fundus images of each eye, reviewed for findings that require follow-up — escalating urgent cases to in-person evaluation.



Sample fundus image — left eye (O.S.)

## Eye Measurements

TAKE ACTION

Refraction-based detection of hyperopia, astigmatism, and myopia, each with patient-friendly guidance and next steps.

# Enterprise-grade security & compliance



## Regulatory compliance

Third-party attestation of HIPAA and SOC 2 controls and best practices.



## Secure cloud infrastructure

Hosted on AWS with GuardDuty, Inspector, and Detective managed security.



## Comprehensive encryption

All cloud data encrypted at rest and in transit against unauthorized access.



## Regular vulnerability assessments

Routine vulnerability scans and annual third-party penetration testing.



## Data retention & disposal

Documented policies govern data lifecycle and secure disposal.



## Strict confidentiality

Confidentiality agreements and ongoing security training for all personnel.

HIPAA Compliant · AICPA SOC 2 · AWS

# Data asset governance & monetization readiness



## Patient consent framework

Explicit opt-in consent at screening covers de-identified research and commercial data use.



## De-identification standard

HIPAA Expert Determination methodology for imaging datasets; Safe Harbor for structured data.



## Partner data rights

Commercial agreements preserve EyeCheq ownership of device-generated imaging and derived analytics.



## Multimodal linkage

Retinal imaging paired with same-visit lab biomarkers — a dataset combination unavailable elsewhere at scale.



## Monetization pathways

Pharma R&D licensing, AI model development, payer risk analytics — pursued only under BAA/DUA governance.



## Ad & media compliance

Sponsored content is opt-in, non-PHI targeted, and clearly disclosed — no patient data sold to advertisers.

HIPAA Compliant · BAA / DUA Governed · Patient Opt-In